

## BiolInvent Q3 2023 - One Step Forward on the Road to Partnering with BI-1808

Redeye comments on the third quarter report of BiolInvent. All projects are progressing. Importantly, BI-1808 is the second program, after BI-1206, to advance into phase II. The subcutaneous version of BI-1206 is being studied with results expected by H1 2024 in lymphoma.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

[BiolInvent Q3 2023 - One Step Forward on the Road to Partnering with BI-1808](#)